Seeking Alpha

MannKind addresses critics with FAQ list

  • Shares of MannKind (MNKD) rise 4.3% premarket apparently in response to an SEC filing (8-K) which announces the publication of a series of FAQs (regarding the Affinity trial results) and responses from the company.
  • MNKD addresses the perceived discrepancy between the 0.4% change in HbA1c observed in Affinity 2 and the 0.5% change the original study design appeared to have called for the demonstrate superiority. There's nothing new here. The company says the 0.5% figure was related to the design of the trial and that the results were "extremely significant" — that's the same thing they said on the conference call.
  • Also addressed is Summer Street's now infamous "unprecedented" comment regarding data on the MedTone inhaler. MNKD says the performance of MedTone and the Gen2 device is "comparable" and, without mentioning any names, calls Summer Street's analysis "alarmist" and "subjective."
  • Investors can read the full FAQ list here.
Comments (8)
  • tomlewis727
    , contributor
    Comments (11) | Send Message
     
    Big news, thanks MannKind for looking out for your shareholders whom have taken an unnecessary beating the past couple weeks.
    27 Aug 2013, 09:02 AM Reply Like
  • wecap
    , contributor
    Comments (38) | Send Message
     
    Yes we have, have 7000 shares, I am all in. Gambler yes. Long and strong and down a ton.
    27 Aug 2013, 09:11 AM Reply Like
  • capbaron
    , contributor
    Comments (2) | Send Message
     
    Individaul investors need to be careful about getting out of MNKD and running for the hills based upon a lot of the negiative news being put out by the short sellers. MNKD's line up of products is going to be a block buster, hang in there and watch your port folio grow.
    27 Aug 2013, 09:58 AM Reply Like
  • NewTampaResident
    , contributor
    Comments (76) | Send Message
     
    Agreed, I think Al Mann and Deerfield that lent them 160M know a lot more about the potential of Alfreeza than the idiots at Summer Street.
    27 Aug 2013, 12:05 PM Reply Like
  • NewTampaResident
    , contributor
    Comments (76) | Send Message
     
    Wish there were laws against the likes of Summer Street.
    Their sensational questioning article on MNKD was nothing more than an attempt to garner attention for themselves.
    I found their article very misleading and I knew it would spook some naive investors.
    I have no respect for Summer Street and would never do business with them, ever.
    27 Aug 2013, 12:04 PM Reply Like
  • SarahKnows
    , contributor
    Comments (71) | Send Message
     
    As George Rho said in his SA reaffirmation of MNKD:

     

    "Why should management respond to some completely unknown author who received $50 for contributing a poorly researched article that The Motley Fool decided to publish? And who (or what) the heck is Summer Street, which apparently questioned the supposed absence of some data that was addressed, satisfactorily, in our opinion, during last Wednesday's conference call. Full disclosure, Summer Street is a name we heard for the first time last Friday, perhaps we need to get out more. " His comment speaks for itself.

     

    http://bit.ly/1dn6DWn
    27 Aug 2013, 12:31 PM Reply Like
  • vireoman
    , contributor
    Comments (838) | Send Message
     
    Don't let disdain for short-sellers keep you from doing due-diligence. For example, the convenience of the Dreamboat inhaler is an asset. However, the diminished efficacy of Afrezza in comparison to Novolog is a liability. Will this lead to fewer prescriptions from doctors than is currently anticipated? Another question relates to the long-term effects of inhalable-insulin on lung functions. It is expected that the FDA will approve Afrezza/Dreamboat, but there is also a likelihood of the FDA mandating additional, highly-expensive, long-term trials investigating that issue post-approval. Could this serve as a deterrent to a partnership with 'big pharma?' If you are long MNKD (as I was until yesterday), there are legitimate questions that need answers and will serve as a drag on the share-price well into the future. Good luck.
    27 Aug 2013, 01:07 PM Reply Like
  • rrobster
    , contributor
    Comments (116) | Send Message
     
    Motley Fool is officially on my "banned and don't read" list.
    27 Aug 2013, 02:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)